Pavella Therapeutics [PVLA] vs Regeneron [REGN] Detailed Stock Comparison

Pavella Therapeutics Inc.

NASDAQ
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Pavella Therapeutics Inc. wins in 2 metrics, Regeneron Pharmaceuticals, Inc. wins in 13 metrics, with 0 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Pavella Therapeutics Inc. Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) 13.69 18.00 Pavella Therapeutics Inc.
Price-to-Book Ratio 56.22 2.45 Regeneron Pharmaceuticals, Inc.
Debt-to-Equity Ratio 65.73 9.51 Regeneron Pharmaceuticals, Inc.
PEG Ratio -19.91 -4.80 Regeneron Pharmaceuticals, Inc.
EV/EBITDA -50.42 16.72 Regeneron Pharmaceuticals, Inc.
Profit Margin (TTM) 0.00% 31.41% Regeneron Pharmaceuticals, Inc.
Operating Margin (TTM) 0.00% 23.13% Regeneron Pharmaceuticals, Inc.
EBITDA Margin (TTM) N/A 23.13% N/A
Return on Equity -92.10% 14.86% Regeneron Pharmaceuticals, Inc.
Return on Assets (TTM) -32.65% 5.91% Regeneron Pharmaceuticals, Inc.
Free Cash Flow (TTM) $-25.01M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return 334.37% 15.66% Pavella Therapeutics Inc.
Price-to-Sales Ratio (TTM) N/A 5.50 N/A
Enterprise Value $1.78B $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio N/A 4.95 N/A
Gross Profit Margin (TTM) N/A 84.95% N/A
Revenue per Share (TTM) $0 $137 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $-3.71 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) N/A 0.40 N/A
Short % of Float 17.65% 2.55% Regeneron Pharmaceuticals, Inc.

Pavella Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

PVLA
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Pavella Therapeutics Inc.7.08%10.70%1.99%-7.57%30.94%16.18%
Regeneron Pharmaceuticals, Inc.0.46%0.60%-11.93%-18.75%-18.29%-20.78%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Pavella Therapeutics Inc.334.37%51.13%-61.47%-19.04%-50.54%-50.54%
Regeneron Pharmaceuticals, Inc.15.66%-21.83%13.80%72.82%1,033.17%4,804.97%

Performance & Financial Health Analysis: Pavella Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

MetricPVLAREGN
Market Information
Market Cap i$1.77B$80.98B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i196,250642,495
90 Day Avg. Volume i266,093617,765
Last Close$116.51$614.98
52 Week Range$20.20 - $151.18$503.25 - $821.11
% from 52W High-22.93%-25.10%
All-Time High$780.00 (Feb 12, 2018)$1,211.20 (Aug 26, 2024)
% from All-Time High-85.06%-49.23%
Growth Metrics
Quarterly Revenue GrowthN/A0.03%
Quarterly Earnings GrowthN/A-0.08%
Financial Health
Profit Margin (TTM) i0.00%0.31%
Operating Margin (TTM) i0.00%0.23%
Return on Equity (TTM) i-0.92%0.15%
Debt to Equity (MRQ) i65.739.51
Cash & Liquidity
Book Value per Share (MRQ)$2.26$304.65
Cash per Share (MRQ)$4.05$83.86
Operating Cash Flow (TTM) i$-25,006,000$4.98B
Levered Free Cash Flow (TTM) i$-18,630,500$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: Pavella Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

MetricPVLA (Apr 26, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i13.6918.00
Forward P/E i-19.9114.21
PEG Ratio i-19.91-4.80
Price to Sales (TTM) iN/A5.50
Price to Book (MRQ) i56.222.45
Market Capitalization
Market Capitalization i$1.77B$80.98B
Enterprise Value i$1.78B$70.98B
Enterprise Value Metrics
Enterprise to Revenue iN/A4.95
Enterprise to EBITDA i-50.4216.72
Risk & Other Metrics
Beta iN/A0.40
Book Value per Share (MRQ) i$2.26$304.65

Financial Statements Comparison: Pavella Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricPVLA (2025)REGN (2025)
Revenue/Sales i014.34B
Cost of Goods Sold iN/A2.10B
COGS % of Revenue i-14.6%
Gross Profit iN/A12.24B
Gross Margin i-85.4%
Research & Development i22.84M5.85B
Operating Income (EBIT) i-38.60M3.70B
Operating Margin i-25.8%
EBITDA i-35.29M5.00B
EBITDA Margin i-34.8%
Pre-Tax Income i-41.72M5.23B
Pre-Tax Income % of Revenue i-36.5%
Income Tax i0725.80M
Income Tax % of Revenue i-5.1%
Net Income (Profit) i-41.72M4.50B
Profit Margin i-31.4%

Balance Sheet & Liquidity Metrics

MetricPVLA (2025)REGN (2025)
Cash & Equivalents i57.98M3.12B
Total Current Assets i58.99M18.02B
Total Current Assets % of Revenue i-125.7%
Total Current Liabilities i11.34M4.37B
Total Current Liabilities % of Revenue i-30.5%
Long-Term Debt i431,0002.71B
Long-Term Debt % of Revenue i-18.9%
Total Shareholders Equity i27.98M31.26B
Retained Earnings i-135.45M35.80B
Retained Earnings % of Revenue i-249.6%
Property, Plant & Equipment i01.54B

Cash Flow Statement Comparison

MetricPVLA (2025)REGN (2025)
Operating Cash Flow i-25.68M6.30B
Operating Cash Flow % of Revenue i-43.9%
Capital Expenditures iN/A0
Free Cash Flow i-25.01M3.77B
FCF Margin i-26.3%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/A-3.97B

Short Interest & Institutional Ownership Analysis

MetricPVLAREGN
Shares Short i2.18M2.55M
Short Ratio i7.504.46
Short % of Float i17.65%2.55%
Shares Outstanding i12.38M105.72M
Float Shares i9.27M98.55M
% Held by Insiders i17.66%1.98%
% Held by Institutions i72.29%91.08%
% Held by Public i10.05%6.94%

Dividend Analysis & Yield Comparison: Pavella Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

MetricPVLAREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026